| scholarly article | Q13442814 |
| P50 | author | Shitij Kapur | Q20713543 |
| Diana Prata | Q46215608 | ||
| P2093 | author name string | Andrea Mechelli | |
| P921 | main subject | psychosis | Q170082 |
| biomarker | Q864574 | ||
| P304 | page(s) | 134-141 | |
| P577 | publication date | 2014-05-27 | |
| P1433 | published in | Neuroscience & Biobehavioral Reviews | Q15709986 |
| P1476 | title | Clinically meaningful biomarkers for psychosis: a systematic and quantitative review | |
| P478 | volume | 45 |
| Q36148525 | A Neuroanatomical Signature for Schizophrenia Across Different Ethnic Groups |
| Q89296095 | A Roadmap for the Development of Applied Computational Psychiatry |
| Q89620159 | Are There Any Biomarkers for Pedophilia and Sexual Child Abuse? A Review |
| Q57612212 | Behavioural biomarkers and mobile mental health: a new paradigm |
| Q37069020 | Biomarkers in Psychiatry - A Critique |
| Q55021168 | Blood Gene Expression Profile Predicts Response to Antipsychotics. |
| Q39631370 | Can Bayesian Theories of Autism Spectrum Disorder Help Improve Clinical Practice? |
| Q36307544 | Converging models of schizophrenia--Network alterations of prefrontal cortex underlying cognitive impairments |
| Q37447215 | Defining Precision Medicine Approaches to Autism Spectrum Disorders: Concepts and Challenges |
| Q50742637 | Evaluation of resting state gamma power as a response marker in schizophrenia. |
| Q36259772 | GAD1 Gene Expression in Blood of Patients with First-Episode Psychosis |
| Q38993769 | Latent variable analysis of positive and negative valence processing focused on symptom and behavioral units of analysis in mood and anxiety disorders |
| Q34906902 | Neural correlates of inhibition and contextual cue processing related to treatment response in PTSD. |
| Q38425649 | Neuroimaging Biomarkers for Psychosis |
| Q38926246 | New drug developments in psychosis: Challenges, opportunities and strategies |
| Q38547002 | Physical Exercise Alleviates Health Defects, Symptoms, and Biomarkers in Schizophrenia Spectrum Disorder |
| Q56959104 | Schizophrenia |
| Q38223276 | Targeting of NMDA receptors in new treatments for schizophrenia |
| Q33827324 | The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders |
| Q40014174 | The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis |
| Q52687829 | The Myth of Optimality in Clinical Neuroscience. |
| Q47710690 | The Role of Biomarkers in Research on Caregivers for Cancer Patients: A Scoping Review. |
| Q90728397 | The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia |
| Q50586484 | The functional and clinical relevance of childhood trauma-related admixture of affective, anxious and psychosis symptoms. |
| Q35142665 | Toward an online cognitive and emotional battery to predict treatment remission in depression |
| Q38803934 | Towards diagnostic markers for the psychoses |
| Q92093093 | Translating research findings into clinical practice: a systematic and critical review of neuroimaging-based clinical tools for brain disorders |
| Q30928632 | What is the impact of genome-wide supported risk variants for schizophrenia and bipolar disorder on brain structure and function? A systematic review |
| Q55023835 | What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? |
Search more.